A tale of two molecules: Nitric oxide and asymmetric dimethylarginine

Acta Cardiologica Sinica

Volumn 20, Issue 4, 2004, Pages 201-211

  Lin, Ken Y ^a,b   Lin, Shih Chung ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Lin Heart Clinic   (Taiwan)

^d Lin Heart Clinic   (Taiwan)

Author keywords

Asymetric dimethyl arginine; Endothelium; Nitric oxide; Nitric oxide synthesis (NOS)

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 8; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; REVIEW; VASCULAR ENDOTHELIUM;

EID: 13844271135     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000;36:2287-95.
2. Tsao PS, Theilmeier G, Singer AH, et al. L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:1529-33.
3. Shukla SD, Paul A, Klachko DM. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb Res 1992;66:239-46.
4. Ignarro LJ, Buga GM, Wei LH, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle proliferation. Proc Natl Acad Sci 2001;98(7):4202-8.
5. Cooke JP and Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 1997;48:489-509.
6. Van de Ree MA, Huisman MV, de Man FH, et al. Impaired endothelium-dependent and independent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovas Res 2001;52:299-305.
7. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:H321-6.
8. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-92.
9. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
10. St linger MC, Tsao PS, Her J-H, et al. Homocysteine impairs the NO synthase pathway: role of ADMA. Circulation 2001;104:2569-75.
11. Iyengar R, Stuehr DJ, Marietta MA. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. Proc. Natl. Acad. Sci 1987;84:6369-73.
12. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997;87:E19-29.
13. Harrison DJ. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7.
14. Busse R and Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990;265:133-6.
15. Forstermann U, Pollock JS, Schmidt HH, et al. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the paniculate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci 1991;88:1788-92.
16. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
17. Hecker M, Mitchell JA, Harris HJ, et al. Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun 1990;167:1037-43.
18. Flam BR, Hartmann PJ, Harrell-Booth M, et al. Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 2001;5:187-97.
19. Girerd XJ, Hirsch AT, Cooke JP, et al. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990;67:1301-8.
20. Drexler H, Zeiher AM, Meinzer K, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
21. Closs EI, Basha FZ, Habermeier A, et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1:6573.
22. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
23. Fulton D, Fontana J, Sowa G, et al. Localization of endothelial nitric oxide synthesis phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane define the existence of 2 pools of enzymes. J Biol Chem 2002.8;277(6):4277-84.
24. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
25. Kielstein J, Boeger R, Bode-Boeger S, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
26. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6.
27. Surdacki A, Nowicki M, Sandmann, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8.
28. Fujiwara N, Osanai T, Kamada T, et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61.
29. Abbasi F, Asagami T, Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3.
30. St linger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
31. Lundman P, Erikson MJ, St linger MC, et al. Mid-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-6.
32. Yoo JH and Lee SC. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158:425-30.
33. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30.
34. Boeger RH, Bode-Boeger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiolol 1998;32:1336-44.
35. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6.
36. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
37. Zoccali C, Bode-B er S, Mallamaci F, et al. Plasma Concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
38. Kurose I, WoIf R, Grisham MB, et al. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am J Physiol 1995;268:H2224-31.
39. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthesis. Am J Physiol 1995;269:H1522-7.
40. Ber RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87(2):99-105.
41. Jacobi J, Schneider MP, John S, et al. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens 2002;3:525-30.
42. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biolo 2001;8:679-83.
43. Marra M, Bonfigli AR, Testa R, et al. High-performance liquid Chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal. Biochem 2003;318(1):13-7.
44. Teerlink T, Nijveldt RJ, de Jong S, et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303(2):131-7.
45. Pi J, Kumagai Y, Sun G, et al. Improved method for simultaneous determination of L-arginine and its mono- and dimethylated metabolites in biological samples by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;742(1):199-203.
46. Causse E, Siri N, Arnal JF, et al. Determination of asymmetrical dimethylarginine by capillary electrophoresis-laser-induced fluorescence. J Chromatogr B Biomed Sci Appl 2000;741(1):77-83.
47. Lin KY and Cooke JP. Acute administration of asymmetric dimethylarginine reduces insulin sensitivity in mice [abstract submitted to American Heart Association 2003 Scientific Sessions].
48. Monti LD, Barlassina C, Citterio L, et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003;52(5):1270-5.